Compare Sanofi SA (SNY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TG Therapeutics Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Sanofi SA is far larger — about 12.7× TG Therapeutics Inc's market cap, and Sanofi SA pays a 5.5% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SNY | TGTX | |
|---|---|---|
Market Cap | $104.83B | $8.26B |
Sector | Health | Health |
52-Week High | $52.34 | $59.06 |
52-Week Low | $41.33 | $26.39 |
Enterprise Value | $121.32B | $8.50B |
Dividend Yield | 5.5% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
